92 related articles for article (PubMed ID: 20970638)
1. Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant.
Jiménez-Pérez M; Sáez-Gómez AB; Mongil Poce L; Lozano-Rey JM; de la Cruz-Lombardo J; Rodrigo-López JM
Transplant Proc; 2010 Oct; 42(8):3167-8. PubMed ID: 20970638
[TBL] [Abstract][Full Text] [Related]
2. Late onset of hepatitis B virus reactivation following hematopoietic stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy.
Milazzo L; Corbellino M; Foschi A; Micheli V; Dodero A; Mazzocchi A; Montefusco V; Zehender G; Antinori S
Transpl Infect Dis; 2012 Feb; 14(1):95-8. PubMed ID: 21749588
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir therapy for lamivudine resistance following liver transplantation.
Neff GW; Nery J; Lau DT; O'Brien CB; Duncan R; Shire NJ; Ruiz P; Nery C; Montalbano M; Muslu H; Safdar K; Schiff ER; Tzakis AG; Madariaga JR
Ann Pharmacother; 2004 Dec; 38(12):1999-2004. PubMed ID: 15507498
[TBL] [Abstract][Full Text] [Related]
4. Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen.
Rago A; Lichtner M; Mecarocci S; Marocco R; Cenfra N; Belvisi V; Del Borgo C; Cimino G; Mastroianni CM
Antivir Ther; 2010; 15(6):929-32. PubMed ID: 20834107
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients.
Fernández I; Loinaz C; Hernández O; Abradelo M; Manrique A; Calvo J; Manzano M; García A; Cambra F; Castellano G; Jiménez C
Transpl Infect Dis; 2015 Oct; 17(5):695-701. PubMed ID: 26257166
[TBL] [Abstract][Full Text] [Related]
6. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Benhamou Y; Fleury H; Trimoulet P; Pellegrin I; Urbinelli R; Katlama C; Rozenbaum W; Le Teuff G; Trylesinski A; Piketty C;
Hepatology; 2006 Mar; 43(3):548-55. PubMed ID: 16496322
[TBL] [Abstract][Full Text] [Related]
7. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
Alvarez-Uria G; Ratcliffe L; Vilar J
HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695
[TBL] [Abstract][Full Text] [Related]
9. Management of severe acute to fulminant hepatitis B: to treat or not to treat or when to treat?
Tillmann HL; Zachou K; Dalekos GN
Liver Int; 2012 Apr; 32(4):544-53. PubMed ID: 22099371
[TBL] [Abstract][Full Text] [Related]
10. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
[TBL] [Abstract][Full Text] [Related]
11. Potency of tenofovir in chronic hepatitis B: mono or combination therapy?
Reijnders JG; Janssen HL
J Hepatol; 2008 Mar; 48(3):383-6. PubMed ID: 18191272
[No Abstract] [Full Text] [Related]
12. Drug therapy: tenofovir.
Lok AS
Hepatology; 2010 Aug; 52(2):743-7. PubMed ID: 20597070
[No Abstract] [Full Text] [Related]
13. Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
Jain MK; Comanor L; White C; Kipnis P; Elkin C; Leung K; Ocampo A; Attar N; Keiser P; Lee WM
J Viral Hepat; 2007 Mar; 14(3):176-82. PubMed ID: 17305883
[TBL] [Abstract][Full Text] [Related]
14. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
Audsley J; Arrifin N; Yuen LK; Ayres A; Crowe SM; Bartholomeusz A; Locarnini SA; Mijch A; Lewin SR; Sasadeusz J
HIV Med; 2009 Apr; 10(4):229-35. PubMed ID: 19178592
[TBL] [Abstract][Full Text] [Related]
15. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.
Sheldon J; Camino N; Rodés B; Bartholomeusz A; Kuiper M; Tacke F; Núñez M; Mauss S; Lutz T; Klausen G; Locarnini S; Soriano V
Antivir Ther; 2005; 10(6):727-34. PubMed ID: 16218172
[TBL] [Abstract][Full Text] [Related]
16. Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.
Matthews GV; Cooper DA; Dore GJ
Antivir Ther; 2007; 12(1):119-22. PubMed ID: 17503756
[TBL] [Abstract][Full Text] [Related]
17. Entecavir is an optional agent to prevent hepatitis B virus (HBV) reactivation: a review of 16 patients.
Watanabe M; Shibuya A; Takada J; Tanaka Y; Okuwaki Y; Minamino T; Hidaka H; Nakazawa T; Koizumi W
Eur J Intern Med; 2010 Aug; 21(4):333-7. PubMed ID: 20603047
[TBL] [Abstract][Full Text] [Related]
18. Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus.
Bani-Sadr F; Palmer P; Scieux C; Molina JM
Clin Infect Dis; 2004 Oct; 39(7):1062-4. PubMed ID: 15472862
[TBL] [Abstract][Full Text] [Related]
19. Proper antiviral therapy for hepatitis B virus-associated acute-on-chronic liver failure.
Liu T; Zhang C; Wang Y
Hepatology; 2011 Aug; 54(2):747-8. PubMed ID: 21360719
[No Abstract] [Full Text] [Related]
20. [Tenofovir, An antiviral agent with activity against HIV infections and hepatitis B].
Taéron C
Rev Infirm; 2009 Sep; (153):49-51. PubMed ID: 19771814
[No Abstract] [Full Text] [Related]
[Next] [New Search]
